“We are proud to announce the agreement with Novozymes which expands our product portfolio within probiotics for specific disease areas in the Nordics. The agreement is an extension of the great collaboration between our two companies for PrecisionBiotics Alflorex®, which we launched in 2019, and demonstrates the value of Navamedic’s local competence and insight in important disease areas and consumer needs” says Kathrine Gamborg Andreassen, CEO in Navamedic ASA.

The special 1714-Serenitas® live culture in Zenflore® was discovered and developed in partnership with scientists and clinicians from one of the world’s leading centres of research on the microbiome and the gut-brain axis, the APC Microbiome Institute at University College Cork, Ireland. Clinical studies have demonstrated that Bifidobacterium longum 1714 improves the ability to handle stressful situations, supports mental performance and combat mental fatigue. Zenflore® also contains selected Vitamin Bs which contributes to the reduction of fatigue and to sustain normal psychological ability.

Kathrine Gamborg Andreassen continues: “Navamedic focuses on products within specialty pharma, medical nutrition and consumer health. Zenflore® strengthens our position within consumer healthcare wherein we see a great potential for development of products and categories – like stress and mental health in this case. The agreement has a term of eight years with automatic renewal and strengthens our position in the entire Nordic region, which is our most important home market.”

Steve Howson, Head of B2C at Novozymes One Health commented: “We are delighted to have reached agreement with our colleagues at Navamedic to launch Zenflore® in the Nordic region. We already have a strong and successful partnership built on the launch of Alflorex® in Norway, Denmark and Netherlands over the last few years. We look forward to working with the Navamedic team to bring Zenflore® to consumers across the region.”

PrecisionBiotics Group has for more than 20 years developed products based upon living bacterial cultures (probiotics) in collaboration with scientists and clinicians at the APC Microbiome Institute. Commercialised products are clinically proven in Europe and USA. PrecisionBiotics Group was acquired by the Danish company NovoZymes A/S in 2020.

For further information, please contact:

Kathrine Gamborg Andreassen, CEO, Navamedic

Mobile: +47 951 78 680

E-mail: kathrine@navamedic.com

Lars Hjarrand, CFO, Navamedic

Mobile: +47 917 62 842

E-mail: lars.hjarrand@navamedic.com

About Navamedic

Navamedic ASA is a Nordic pharma company and reliable provider of high-quality products, delivered to hospitals and through pharmacies, meeting the specific needs of patients and consumers by leveraging its highly scalable market access platform, leading category competence and local knowledge. Navamedic is present in all the Nordic countries, the Baltics and Benelux, with sales representation in the UK and Greece. Navamedic is headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange (ticker: NAVA). For more information, please visit www.navamedic.com

About Novozymes

Novozymes is the world leader in biological solutions. Together with customers, partners and the global community, we find biological answers to preserve the planet’s resources and help build better lives. As the world’s largest provider of enzyme and microbial technologies, our bioinnovation enables increased health and nutritional benefits, higher agricultural yields, improved washing, energy-efficient production, renewable fuel and many other benefits that we rely on today and in the future. We call it Rethink Tomorrow. www.novozymes.com